RxDoctor Payments Data

Danielle Mallory, APRN

Family · Uncasville, CTNPI 1003478686

Payments from drug & device makers

$7,207in general payments, 2019–2025

Across 358 payments — averaging $20.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • GSK$765
  • AstraZeneca$556
  • Novo Nordisk$506
  • Phathom Pharmaceuticals, Inc.$500
  • Bausch Health US, LLC$216
  • plus $2K from 27 others

What the payments were for

  • Food & beverage$7,207100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,207 in reported general payments places this provider in the 95th percentile of 1,596 family providers in Connecticut.

See all family providers in Connecticut

Medicare billing

Part B allowed, 2024
$20,642
Medicare patients
66
Services billed
283

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol13$22,131
Trelegy ElliptaFluticasone/Umeclidin/Vilanter12$19,605
Lamotrigine ErLamotrigine22$1,248
Omeprazole47$1,006
Albuterol Sulfate HfaAlbuterol Sulfate55$910
Fluticasone Propionate40$852
Gabapentin56$818
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine11$780
Paroxetine ErParoxetine Hcl11$730
Atorvastatin Calcium62$535
Duloxetine Hcl26$529
Losartan Potassium81$523
Ezetimibe13$519
Levothyroxine Sodium57$480
Bupropion XlBupropion Hcl20$457

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$556$22,13113 claims
GSKTrelegy Ellipta$765$19,60512 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,596 family providers in Connecticut.

Other family in Uncasville

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →